India bans two-ingredient cold medicines for children under four
The government has prohibited the manufacture, sale and distribution of fixed-dose cold-medicine combinations containing chlorpheniramine maleate and phenylephrine hydrochloride for children under four. The rule takes effect upon Official Gazette publication and requires prominent warnings on packs, inserts and promotional material.
What happened
Ministry of Health and Family Welfare · India banned manufacture, sale and distribution of cold-medicine fixed-dose combinations containing chlorpheniramine
Key facts
- Children below 4 years of age
- April 2025
- Section 26A
- Drugs and Cosmetics Act, 1940
- 50 restricted combinations in the last year
Why this matters
Prioritize partnerships or acquisitions involving compliant paediatric symptom-relief portfolios, pharmacovigilance capabilities and rapid packaging-compliance infrastructure.
What to watch
- Official Gazette publication date and any implementation grace period or clarification from CDSCO or state drug controllers.
- State-level enforcement activity, pharmacy inspections, seizure notices or manufacturer recall instructions.
- Manufacturer reformulations, revised labels and launches of single-ingredient or age-segmented paediatric products.
- Availability and pricing of substitute paediatric-care products, especially saline, fever relief, cough-support and wellness categories.
- Additional scrutiny of other paediatric fixed-dose combinations or broader OTC cold-and-cough labeling requirements.
- E-pharmacy delistings, marketplace policy updates and consumer search-volume spikes for banned product brands.
- Immediately identify all SKUs containing chlorpheniramine maleate plus phenylephrine hydrochloride that are labeled, positioned or potentially used for children under four.
- Freeze purchase orders, warehouse dispatches, store transfers and online listings for affected formulations pending Gazette-effective compliance confirmation.
- Quarantine existing stock, document batch-level inventory and coordinate supplier returns, credit notes, destruction or relabeling procedures as permitted.
- Update pharmacy POS prompts and e-commerce age-gating so pharmacists and customers receive a clear under-four restriction alert.
- Train pharmacists, call-center teams and store staff on permitted alternatives, escalation to paediatricians and consistent consumer messaging.
- Audit shelf labels, product inserts, digital product pages, search advertising and promotional materials for required warnings and prohibited claims.